Epidemiological, Clinical, Microbiological and Outcome Description of Patients With Klebsiella sp Meningitis

Meningitis Clinical Trial

— KlebsieLCR  

Official title:

Epidemiological, Clinical, Microbiological and Outcome Description of Patients With Klebsiella sp Meningitis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03967210
• Other study ID #: KlebsieLCR
• Status: Completed
• Start date: July 5, 2019
• Est. completion date: January 13, 2020

Study information

• Verified date: August 2021
• Source: Groupe Hospitalier Paris Saint Joseph
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Klebsiella pneumoniae is implicated in the occurrence of severe pneumonia. Most Klebsiella pneumoniae infections are associated with care and occur in patients with compromised immune defenses. More recently, cases of hepatic abscess and acute community meningitis related to strains of Klebsiella pneumoniae have been reported. The mortality of these infections is important, most often due to a delayed diagnosis. The poor prognostic factors reported in the literature for very low numbers are: advanced age, coma, septic shock, glyceryachia <10mg / dL and proteinuria> 750 mg / dL. In addition, no study has specifically focused on the factors of occurrence and factors associated with Klebsiella sp. Indeed, meningitis related to Klebsiella pneumoniae seems to be a rare but probably underestimated event whose risk factors, clinical presentation, microbiological are little known and the treatment modalities of this severe infection are not codified.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 132
• Est. completion date: January 13, 2020
• Est. primary completion date: December 31, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Man or Woman whose age = 18 years

• Patient with meningitis Klebsiella sp., hospitalized in one of the hospitals of the Clinical Microbiology Group

• Francophone patient

Exclusion Criteria:

• Patient under tutorship or curatorship

• Patient deprived of liberty

• Patient under safeguard of justice

• Patient opposing his participation

Related Conditions & MeSH terms

• Meningitis

Locations

Country	Name	City	State
France	CHU Brest	Brest
France	CHU Caen	Caen
France	Hôpital henri Mondor	Créteil
France	CHU Lyon	Lyon
France	CHU Nantes	Nantes
France	CHU Nice	Nice
France	CHU Kremlin Bicetre	Paris
France	Groupe Hospitalier Paris Saint-Joseph	Paris
France	Hôpital Cochin	Paris
France	Hôpital Foch	Paris
France	Hôpital Lariboisière	Paris
France	Hôpital Necker Enfants Malades	Paris
France	Hôpital Sainte Anne	Paris
France	CHU Poitiers	Poitiers
France	CHU Reims	Reims
France	CHU Rennes	Rennes
France	CHU Strasbourg	Strasbourg
France	CHU Tours	Tours

Sponsors (1)

Lead Sponsor	Collaborator
Groupe Hospitalier Paris Saint Joseph

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Characterize meningitis with Klebsiella pneumoniae	This corresponds to characterize Klebsiella pneumoniae meningitis, portal entry, secondary infection, associated antibiotic and associated therapies and the clinical course of patients.	Day 1